Brought to you by 
Ipsen, Inspiration sell off OBI1 assets to Baxter International
01 Mar 2013
Executive Summary
Inspiration Biopharmaceuticals Inc. and Ipsen have granted Baxter International Inc. global rights to OBI1, a recombinant porcine Factor VIII in Phase III for congenital hemophilia A with inhibitors and for acquired hemophilia A.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen, Inspiration sell off OBI1 assets to Baxter International
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice